[ANMCO立场论文:高伤心肌病:从诊断到治疗]
Cristina Chimenti1, Attilio Iacovoni2, Andrea Montalto3
1U.O.C. Malattie Apparato Cardiovascolare, AOU Policlinico Umberto I, Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Roma.
概括
增高性心肌病变 (HCM) 是一种遗传性心脏病,影响1:500人. 新的肌抑制药物为阻塞性HCM提供了新的治疗选择,改善了患者的护理.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 超性心肌病 (HCM) 是一种普遍存在的遗传性心脏病 (1:500) 标志着左心室壁厚度增加.
- 在HCM中,左心室外流通道阻塞是功能减弱,心脏突然死亡和心力衰竭进展的关键因素.
- 对于对标准药物和隔膜缩小疗法耐药的症状阻塞性HCM患者,存在有限的治疗选择.
研究的目的:
- 为了提高心脏病学家对缩性心肌病 (HCM) 的理解.
- 定义HCM的流行病学,遗传学和病理学特征.
- 概述个性化HCM治疗的诊断标准和风险分层方法.
主要方法:
- 综述当前关于多变性心肌病 (HCM) 流行病学,遗传学和病理学的文献.
- 对风险分层的诊断标准和仪器方法的分析.
- 评估新兴的治疗策略,包括新药类.
主要成果:
- HCM的特征是不对称的隔膜缩,往往导致左心室外流通道阻塞.
- 阻塞性HCM显著影响功能能力和预后.
- 一个新的心脏肌肉酶抑制剂类别代表了HCM治疗的重大进步.
结论:
- 准确的临床治疗分类对于最佳的HCM管理至关重要.
- 新的治疗途径,特别是肌抑制剂,正在改变阻塞性HCM护理.
- 这份立场论文旨在指导心脏病专家为个别HCM患者量身定制治疗方法.
相关概念视频
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Anatomy of the Heart
103.5K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
103.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Pulmonary Hypertension: Classification and Pathogenesis
112
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
112
Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K


